Ab Corporate Bond Etf Performance
| EYEG Etf | USD 35.35 0.09 0.26% |
The entity owns a Beta (Systematic Risk) of 0.0852, which signifies not very significant fluctuations relative to the market. As returns on the market increase, AB Corporate's returns are expected to increase less than the market. However, during the bear market, the loss of holding AB Corporate is expected to be smaller as well.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in AB Corporate Bond are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly stable technical and fundamental indicators, AB Corporate is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
1 | Disposition of 627 shares by From Stephen of AB Corporate at 5.11 subject to Rule 16b-3 | 12/16/2024 |
2 | Disposition of 615 shares by From Stephen of AB Corporate at 4.11 subject to Rule 16b-3 | 12/27/2024 |
3 | Disposition of 1641 shares by Mann Brenda of AB Corporate at 0.21 subject to Rule 16b-3 | 12/31/2024 |
4 | Investment Analysis - Stock Traders Daily | 02/12/2025 |
5 | Disposition of 588 shares by From Stephen of AB Corporate at 3.76 subject to Rule 16b-3 | 02/18/2025 |
6 | Disposition of tradable shares by Mann Brenda of AB Corporate at 4.82 subject to Rule 16b-3 | 02/28/2025 |
7 | Disposition of 101 shares by Mann Brenda of AB Corporate at 7.46 subject to Rule 16b-3 | 03/04/2025 |
EYEG |
AB Corporate Relative Risk vs. Return Landscape
If you would invest 3,510 in AB Corporate Bond on December 15, 2024 and sell it today you would earn a total of 25.00 from holding AB Corporate Bond or generate 0.71% return on investment over 90 days. AB Corporate Bond is currently generating 0.0124% in daily expected returns and assumes 0.3443% risk (volatility on return distribution) over the 90 days horizon. In different words, 3% of etfs are less volatile than EYEG, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AB Corporate Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AB Corporate's investment risk. Standard deviation is the most common way to measure market volatility of etfs, such as AB Corporate Bond, and traders can use it to determine the average amount a AB Corporate's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.036
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EYEG |
Estimated Market Risk
| 0.34 actual daily | 3 97% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average AB Corporate is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AB Corporate by adding it to a well-diversified portfolio.
AB Corporate Fundamentals Growth
EYEG Etf prices reflect investors' perceptions of the future prospects and financial health of AB Corporate, and AB Corporate fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on EYEG Etf performance.
| Return On Equity | -103.8 | |||
| Return On Asset | -40.35 | |||
| Current Valuation | 18.1 M | |||
| Shares Outstanding | 7.1 M | |||
| Price To Earning | (0.85) X | |||
| Price To Book | 1.55 X | |||
| Revenue | 12.06 K | |||
| EBITDA | (9.34 M) | |||
| Cash And Equivalents | 3.66 M | |||
| Cash Per Share | 0.29 X | |||
| Total Debt | 308.01 K | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 1.26 X | |||
| Cash Flow From Operations | (8.66 M) | |||
| Earnings Per Share | (1.77) X | |||
| Total Asset | 10.62 M | |||
| Retained Earnings | (108.16 M) | |||
| Current Asset | 6.26 M | |||
| Current Liabilities | 6.16 M | |||
About AB Corporate Performance
By analyzing AB Corporate's fundamental ratios, stakeholders can gain valuable insights into AB Corporate's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if AB Corporate has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AB Corporate has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts. Eyegate Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.| The company reported the previous year's revenue of 12.06 K. Net Loss for the year was (9.47 M) with loss before overhead, payroll, taxes, and interest of (3.55 M). | |
| AB Corporate Bond currently holds about 3.66 M in cash with (8.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29. | |
| Roughly 12.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 101 shares by Mann Brenda of AB Corporate at 7.46 subject to Rule 16b-3 |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in AB Corporate Bond. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
The market value of AB Corporate Bond is measured differently than its book value, which is the value of EYEG that is recorded on the company's balance sheet. Investors also form their own opinion of AB Corporate's value that differs from its market value or its book value, called intrinsic value, which is AB Corporate's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AB Corporate's market value can be influenced by many factors that don't directly affect AB Corporate's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AB Corporate's value and its price as these two are different measures arrived at by different means. Investors typically determine if AB Corporate is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AB Corporate's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.